Eli Lilly and Co. (NYSE:LLY) – Stock analysts at SunTrust Banks lowered their Q4 2016 earnings per share (EPS) estimates for Eli Lilly and in a research note issued to investors on Wednesday. SunTrust Banks analyst J. Boris now anticipates that the firm will post earnings per share of $0.94 for the quarter, down from their prior estimate of $1.03. SunTrust Banks also issued estimates for Eli Lilly and’s FY2018 earnings at $4.45 EPS and FY2020 earnings at $6.19 EPS.
A number of other equities analysts have also issued reports on LLY. Leerink Swann reiterated an “outperform” rating and issued a $105.00 target price on shares of Eli Lilly and in a research report on Saturday, August 13th. Citigroup Inc. reiterated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, November 8th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $88.00 target price for the company in a research report on Thursday, October 20th. JPMorgan Chase & Co. set a $85.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Thursday. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $94.00 target price on shares of Eli Lilly and in a research report on Tuesday, September 27th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $108.34.
Eli Lilly and (NYSE:LLY) opened at 69.12 on Monday. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $88.16. The firm has a market cap of $73.11 billion, a price-to-earnings ratio of 30.07 and a beta of 0.28. The stock has a 50 day moving average of $76.69 and a 200-day moving average of $77.92.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The firm earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.89 EPS.
A number of hedge funds have recently bought and sold shares of the stock. RWC Asset Management LLP raised its stake in Eli Lilly and by 3.7% in the third quarter. RWC Asset Management LLP now owns 712,392 shares of the company’s stock worth $57,177,000 after buying an additional 25,429 shares in the last quarter. ETRADE Capital Management LLC raised its stake in Eli Lilly and by 37.7% in the third quarter. ETRADE Capital Management LLC now owns 12,904 shares of the company’s stock worth $1,036,000 after buying an additional 3,531 shares during the period. D.A. Davidson & CO. raised its stake in Eli Lilly and by 53.1% in the third quarter. D.A. Davidson & CO. now owns 41,009 shares of the company’s stock worth $3,289,000 after buying an additional 14,215 shares during the period. Sheets Smith Wealth Management raised its stake in Eli Lilly and by 28.8% in the third quarter. Sheets Smith Wealth Management now owns 3,801 shares of the company’s stock worth $305,000 after buying an additional 851 shares during the period. Finally, Piedmont Investment Advisors LLC bought a new stake in Eli Lilly and during the third quarter worth about $17,345,000. 75.11% of the stock is owned by institutional investors.
In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of the company’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the sale, the insider now directly owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.20% of the company’s stock.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be paid a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s dividend payout ratio is presently 88.70%.
Eli Lilly and Company Profile